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Abstract
Overtreatment of prostate cancer is a significant problem in the health care of men.
Development of non-invasive imaging tools for improved characterization of prostate lesions
has the potential to reduce overtreatment. In this thesis work, we will evaluate the ability of
tissue sodium concentration obtained from sodium magnetic resonance imaging (sodium-MRI)
to characterize in vivo prostate lesions. Imaging data, including multi-parametric magnetic
resonance imaging (mpMRI) and sodium-MRI, were obtained from a cohort of men with
biopsy-proven prostate cancer and compared to digitized whole-mount histopathology after
prostatectomy. Histopathology was independently graded for Gleason score to be used as the
ground truth of tumour aggression. These imaging data were all accurately co-registered,
allowing for direct comparison of imaging contrast to Gleason score. The results of this thesis
work suggest that tissue sodium concentration assessed by sodium-MRI has utility as a part of
a “non-invasive imaging-assay” to accurately characterize prostate cancer lesions. SodiumMRI can provide clinically useful, complementary information to mpMRI; ultimately leading
to better characterization of prostate lesions throughout the whole prostate. This has potential
to improve patient outcomes of men with low-risk disease who do opt for active surveillance
instead of treatment.
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Chapter 1

1

Introduction
The objective of Chapter 1 is to provide the introductory information about the work

described in Chapters 2 and 3. This includes necessary information about the Prostate
Gland (Section 1.1), Prostate Cancer (Section 1.2), The Sodium Ion in the Tissue
Environment (Section 1.3), 1H Magnetic Resonance Imaging (Section 1.4), and 23Sodium
Magnetic Resonance Imaging (Section 1.5).

1.1 The Prostate Gland
The human prostate gland is situated in the genitourinary region of the male body. This
section provides background information regarding the anatomy and physiology of the
human prostate gland.

1.1.1

Prostate Anatomy
The prostate gland is a compound tubuloalveolar gland of the male reproductive

system. It is situated within the pelvic cavity, in the genitourinary region of a man’s body.
It is located inferior to the bladder and anterior to the rectum. It is both glandular and
muscular. The young prostate weighs approximately 20 grams and is roughly the size of a
golf ball (4 × 2 × 3 cm). Over time, the size of the prostate increases as men age due to
benign conditions such as benign prostatic hyperplasia (BPH) or cancerous conditions such
as adenocarcinoma. It consists of 70% glandular tissue and 30% fibromuscular stroma [1].
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The upper portion of the prostate is called the base and it rests just inferior to the bladder;
the base is adjacent to the bladder. The gland has a conical shape, making the inferior apex
narrower than the superior base [2]. The urethra runs through the middle of the prostate
gland, where it is called the prostatic urethra (Figure 1-1). Two ejaculatory ducts run
through the prostate carrying the seminal composition of semen from the seminal vesicle
into the urethra. The prostate muscles are important to ensure semen moves through the
prostatic urethra and they play a minor role in ejaculation. The gland is divided into four
main distinct zones: peripheral zone (PZ), central zone (CZ), transitional zone (TZ) and
anterior-fibromuscular stroma (Figure 1-1).

Figure 1-1. a) Sagittal cut of the genitourinary region of the male body, illustrating
the in vivo location of the prostate gland relative to the bladder and rectum. Image
adapted from the online program, BioDigital Human. b) Zonal prostate gland
anatomy. The major zones of the gland are identified in the diagram and legend to
the right. Superior, Inferior, Anterior, and Posterior landmarks are provided for
orientation. The plane of an axial image cut is also shown; this is the approximate
orientation of the prostate images shown in this thesis.
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The peripheral zone is a mustache-shaped area which is the largest zone of the prostate.
The peripheral zone comprises approximately three quarters of the glandular prostate tissue
[1] and is the most common site of prostate inflammation (chronic prostatitis). The
peripheral zone is the portion of the gland that is palpated by a physician through the rectum
during a digital rectal exam (DRE). Approximately 70-80% of the prostatic cancers occur
in the PZ [3]. The central zone is located within the superior-posterior portion of the gland,
which surrounds the ejaculatory ducts. The CZ makes up 25% of the glandular tissue but
is associated with very few adenocarcinomas (1-5%) [4]. The transitional zone surrounds
a portion of the prostatic urethra; this zone is known to enlarge as men age, a condition
referred to as benign prostatic hyperplasia (BPH). As this zone enlarges, urethral
obstruction can occur. If growth of an adenoma becomes large enough, compression of the
fibromuscular band occurs. The final zone of the prostate is the anterior-fibromuscular
stroma, located in the apex. This zone consists of muscle fibers and connective tissue.

1.1.2

Prostate Gland Physiology

The prostate gland plays an important role in male reproduction, secreting fluids which
make up a large fraction of the semen volume. Approximately one third of the total volume
of semen is contributed by the prostate gland, these secretions protect and nourish sperm.
The prostatic secretions consist of: the simple sugars fructose and glucose, protein-splitting
enzymes, zinc, and citric acid. Altogether, the prostatic secretions are slightly acidic, this
helps the sperm survive in the basic environment of the vagina. The sugars play a large role
in sperm motility. They are used as a nutrition and energy source to power movement of
the sperm’s flagellum, allowing the sperm to “swim” to the ova and fertilize it. The
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secretory action of the prostate gland is carried out by acini. Acini lumens are lined with
epithelial cells, which are the producers of the prostatic fluid. Therefore, prostatic
secretions are collected in acinar lumens. The lumen-bound prostatic fluid then drains via
a system of ducts, eventually collecting in the prostatic urethra. Prostatic epithelial cells
are classified under two categories, basal and glandular cells. Basal epithelial cells are less
abundant and their role in tissue is less understood; however, one of their responsibilities
is production of the cellular basement membrane. The glandular epithelial cells attach to
the basal epithelial cells and are found abundantly along the acini lumen wall. They are the
active secretory cells in the prostate, responsible for production of prostatic fluid found in
semen. In human cells, approximately 20,000 protein-coding genes are expressed [5]; not
all cells express every gene, as this is determined by tissue specification. Prostate-specific
membrane antigen (PSMA) is a transmembrane, enzymatic protein that is expressed in four
tissues in the body: the prostate epithelium, the kidney’s proximal tubules, the brush border
of the small intestine (jejunum section) and the ganglia of the nervous system. Although it
is expressed in four body locations, its highest expression is within prostate tissue (roughly
100 times greater than any other tissue). Within the prostate gland, PSMA is highly specific
for prostatic epithelial cells. Prostate-specific antigen (PSA) is a protein produced by both
epithelial prostate epithelial cells and prostate cancer cells [6]. It isn’t confined to the
prostate after formation, as PSA is detectable in the blood. PSA functions to liquefy the
semen, liberating the sperm to swim freely [7]. Normal levels of PSA in the seminal fluid
are typically 0.5-5 mg/ml, which is a concentration 106 larger than found in the blood. This
is because retrograde release of PSA into the bloodstream of healthy men is not a common
event; therefore, excessive escape of PSA into the blood is only facilitated by destruction
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of the prostate basement membrane [7]. Normal concentrations of PSA in the blood is not
well defined. Age and racial demographics can influence the range of what is considered
healthy. For men below the age of 50, healthy PSA levels for Asian Americans, African
Americans and Caucasians were seen to be 0 - 2.0 ng/ml, 0 - 2.0 ng/ml, 0 - 2.5 ng/ml,
respectively [8]. These numbers are subject to increase with age, and this is thought to be
associated with a normal, age-related, increase in prostate size.
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1.2 Prostate Cancer
A persistent belief in our society is that “cancer” is a deadly disease that always
needs to be treated as soon as possible; however, this is not always the case. Regardless,
the public maintains this belief. For some types of cancer, like prostate cancer, this
widespread idea has unfortunate implications. Typically, men diagnosed with prostate
cancer have the option to choose either active surveillance or more radical treatment. Men
facing this decision are also faced with uncertainty that is associated with living with
untreated cancer. Additionally, the widespread notion that cancer is always a deadly
disease can lead to men with low-risk cancer choosing treatment even if it was not
necessary for them. This phenomenon is called overtreatment. In this section, we will
outline current statistics regarding prostate cancer, describe the current prostate cancer
grading system, outline how prostate cancer is diagnosed and describe the treatment and
overtreatment of the disease in our health care system.

1.2.1

Prostate Cancer Statistics
One in seven men will be diagnosed with prostate cancer (PCa) in their lifetime,

making it the most common malignancy in males [9]. Post-mortem studies of men who
died from unrelated causes have identified that the instances of prostate cancer in deceased
men was roughly proportionally to their age [10]. For example, in a random population
sample of men 65 years old, approximately 65% of them would have non-aggressive PCa.
In 2017, there were 103,100 new cases of cancer in Canadian men. 20.4% of those cases
were prostate cancer, which was the largest share [9]. Although one in seven men are
diagnosed with this malignancy, the lifetime probability of dying from prostate cancer is

7

just 1 in 28 men. This is much lower than the risk of death for all cancers combined, which
was estimated to be 1 in 3.5 persons [9]. The overall mortality rate for PCa has been steadily
declining by 3.3% every year since 2001, owing to improved treatment techniques for both
early- and late-stage disease. Risk of death associated with prostate cancer has been seen
to rise in men with both diabetes and higher body-mass-index (BMI) [11, 12]. The age of
a man is a strong predictor of instances of new prostate cancer diagnosis. In 2017, there
were 21,300 new cases of prostate cancer diagnosed on Canadian males. The age range of
30-39 was the youngest age group where new diagnosis was made, accounting for just
0.02% of all new diagnosis. The percentage of new cases in relation to age range increases
monotonically with age group up to ages 60-69: 1.7% for men 40-49, 16.9% for men 5059, 38.5% for men 60-69. The most common age group for diagnosis was men 60-69. Men
aged 70-79 accounted for 29% of new diagnosis and males over the age of 80 accounted
for 14% of all new PCa diagnosis. Post-diagnosis, the 5, 10 and 15-year survival rates of
prostate cancer are very high: 99%, 98%, and 96%, respectively. The most common
prostate malignancy is adenocarcinoma accounting for approximately 98% of all prostate
cancer [13]. Adenocarcinoma originates in the epithelial gland cells, which are responsible
for formation of mucus and the prostatic fluid of semen. Adenocarcinomas are most
commonly found in the peripheral zone, where they are palpated during a digital rectal
exam. Of the men with newly-diagnosed prostate cancer, 50% are assigned to the low-risk
cancer group. Low-risk, or indolent cancer has low associate mortality and little chance of
metastasis. The number of low-risk men who do choose active surveillance (AS) is
increasing, as over 50% low-risk men will now opt for AS instead of treatment; however,
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this number is still lower than the number of men who could be properly treated with active
surveillance [14].

1.2.2

Grading Prostate Cancer Aggression
In 1966, Donald F. Gleason established the Gleason Scoring System. He amended

his own system twice (in 1974 and 1977) [15] and had become the clinical standard for
characterizing the aggression of prostate cancer until 2015. Today, grade grouping is used
as the standard to stage the prostate cancer of men. Grade grouping incorporates a patients
Gleason score to separate men into one of five categories that designate increasing levels
of aggression. The Gleason scoring system is based on low-power, microscopic
observation of the morphological features in prostatic tissue samples. Specimens sent for
grading are obtained from either needle-biopsy as tissue cores, or whole prostate gland
sections obtained after radical prostatectomy. Tumour cells are then judged to fit within
five distinct categories, called Gleason grades. These grades range from 1 to 5 and represent
different states of complexity in morphology. Grade 1 is the least aggressive on the scale
and grade 5 is the most aggressive. Figure 1-2 illustrates the cellular and tissue morphology
seen with varying Gleason grades, visualized with histology. Within an identified lesion,
the most prevalent tumour grade is denoted as the primary grade and the second most
prominent grade of lesion in an area becomes the secondary grade. Gleason score (GS) is
a combination of the primary and secondary Gleason grades (GG): Gleason Score =
primary grade + secondary grade.
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Figure 1-2. Cellular and tissue characteristics of Gleason grades 1-5 are shown in
panels from left to right (1-5). On the Gleason Grading System, Grade 1 is the lowest
classification. It is assigned to tumour tissue which is determined to be the least
aggressive. Tumour aggression increases monotonically with Gleason grade until
grade 5. Grade 5 is the highest grade given in this grading system. At grade 4 (see
panel 4), cribriform structures become present in the tissue (larger, pink-filled
structures on the bottom of the grade 4 panel). This figure is adapted from an image
in an article published by Epstein et al. (2005) [16].
The lowest grades of cancer on the Gleason grade scale are grades 1 and 2.
Combinations of these grades result in GS 2-4 (Gleason 1+1, Gleason 1+2, Gleason 2+1,
and Gleason 2+2), which are rarely diagnosed. This is because the accuracy and utility of
giving this assessment is debated. Cores extracted from needle biopsy and assigned
Gleason scores of 2-4 often represent an under-grading of more aggressive lesions [17].
Previous studies showed that 55% of needle biopsies, graded with Gleason scores 2-4,
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showed extra-prostatic extensions after radical prostatectomy [18]. Other research has
associated a very low-risk of patient death within 15 years of Gleason score 2-4 diagnosis
[19]. However, these tumours were obtained through transurethral resection of the prostate
(TURP). Low-volume Gleason score 2-4 tumours found using TURP are often indolent
compared to tumours taken from needle biopsy. In addition, reproducibility of the GS 2-4
diagnosis by urological pathologists is low [17, 20]. The uncertainty associated with GS 24 is problematic for patients who are assigned this score, as this grade of cancer has a low
chance of progression and therefore patients possessing it are not sent for treatment [17].
If we are going to steer patients away from treatment in our healthcare system, we need to
be very confident that GS 2-4 lesions are not under-grading of more aggressive cancer.
Therefore, literature has suggested that there is little risk to patients to instead assign GS
2-4 cancer with a Gleason score of 5 or 6. By doing this, we will be decreasing the chances
of misdiagnosing higher stage foci. Gleason grade 3 from biopsy is a reliable determination
and is the most common Gleason pattern identified on biopsy cores. In GG 3 (Figure 1-2,
category 3), cells are smaller than GG 1 and 2 and infiltration between benign glands is a
common characteristic. Importantly, grade 3 gland cells still have a distinguished border.
Gleason grade 4 is identified as poorly-formed or fused gland cells [21]. Further, at GG 4,
cribriform gland adenocarcinomas are present. All cribriform adenocarcinomas are
classified as ≥ GG 4 [22]. These structures have been seen to be strong predictors of
metastasis in patients with Gleason score 7 cancer at radical prostatectomy [23]. Cribriform
structures are identified on histology as having a sieve-like appearance. Prostate cells with
this cribriform structure have irregular edges and an unrecognizable lumen (Figure 1-2,
category 4). Gleason grade 4 cells are often fused together, with no stroma separating the
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cells. Gleason grade 5 is the highest (most aggressive) grade of cancer than can be assigned
in the Gleason system. Gleason grade 5 tissue has limited gland formation and does not
resemble normal prostate tissue. Common patterns seen in GG 5 include planar sheet of
tumour, individual cells, and long cords of cells [21]. Comedonecrosis is defined as
necrotic tissue in the luminal space. This is an uncommon tissue characteristic but, when
present, is classified as GG 5. Often, Gleason grade 5 is an under-graded cell type [24].
Not shown in Figure 1-2 are the “precancerous conditions” of the prostate, including:
prostatic intraepithelial neoplasia (PIN) and proliferative inflammatory atrophy (PIA) and
benign prostatic conditions such as: BPH and atypical small acinar proliferation (ASAP).
PIN is defined as an abnormal condition of the epithelial cells which line the acini. Since
adenocarcinomas arise from epithelial cells and make up approximately 98% of all prostate
cancers, PIN is identified as a potential precursor to malignancy. Histologically, they
present with prominent nuclei in an existing duct structure. BPH is a non-cancerous
enlargement of the prostate that is a result of the second phase of prostate growth that
begins when men are over 25 years of age. This enlargement squeezes the prostatic urethra
and creates many secondary effects that affect patient quality of life. BPH often presents
with lower urinary tract symptoms [25]. These symptoms are categorized as either voiding
symptoms: weak urine stream and incomplete bladder emptying, or storage symptoms:
frequent need to urinate leading to nocturia [26]. The instances of BPH are high, affecting
50% of men by the time they are 60 [26]. Atypical small acinar proliferation (ASAP) is an
abnormal growth of gland cells in the prostate. ASAP that is suspicious for malignancy
will be identified as groups of cells that are highly suggestive of cancer but are not
diagnostic for carcinoma [27]. ASAP suspicious for malignancy that is discovered after
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core biopsy is highly predictive of subsequent adenocarcinoma on repeat biopsy.
Proliferative inflammatory atrophy (PIA) are identified as frequently occurring, atrophic
prostate lesions. Studies have identified the imbalance between proliferation and apoptosis
in PIA cells [28] which supports its connection with carcinoma. It is a benign lesion with
potential to degenerate into PIN or carcinoma. PIN, ASAP, and PIA are identified as precancerous conditions, but some experts do not think that they necessarily are linked to
increased risk of developing prostate cancer, therefore men with these cell types are not
treated.

1.2.3

Prostate Cancer Diagnosis
The National Comprehensive Cancer Network’s (NCCN) guidelines stipulate that

asymptomatic men can be classified as having suspected prostate cancer after an abnormal
digital rectal exam (DRE). A digital rectal exam is performed by palpating the peripheral
zone of the prostate, to estimate its enlargement. In the early 1900’s DRE screening lead
to improvement of PCa patient staging and thereafter was recommended as an annual
procedure for men over 50 [29]. However, the nature of the exam is uncomfortable for the
patient and depends on a subjective, skill-dependent evaluation by the physician about the
size and stiffness of the gland. Presently, DRE is used in conjunction with other tools to
aid in diagnosis of prostate cancer. One of these tools is the PSA blood test, which has been
seen to help detect prostate cancer. In previous study, 33% of men with PSA levels above
4 ng/ml were seen to have biopsy detected malignancy [30]. The lack of specificity that
high PSA levels has for prostate cancer is likely do to unforeseen PSA-elevating
circumstances such as BPH, prostate manipulation during a DRE and/or biopsy, and
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prostatitis [31]. Another diagnosis technique that is employed after a patient presents in the
clinic with a suspicious DRE and elevated blood PSA levels is a 2D transrectal ultrasound
(TRUS)-guided biopsy. The TRUS-guided biopsy is the clinical standard for prostate
cancer diagnosis. In this technique, 12 needles are directed into the prostate gland on
trajectories that are guided by an ultrasound probe. These needles extract tissue cores,
which are subsequently pathologically examined for Gleason grade [32]. Based on the
Gleason scores given, a treatment recommendation is made for patients. However, the
Gleason graded biopsy tissue often miss-characterizes the stage of lesions, either through
over- or under-estimation [33]. This can been attributed in part to tangential sectioning,
where the needles used for tissue extraction alter the integrity of the cells sampled in the
cores, leading to an incorrect determination of cell grade [34]. Additionally, the nature of
biopsy technique samples less than 0.5% of the entire prostate gland, leading to high falsenegative rates (21-47%), which often results in repeated biopsy [35]. In addition to Gleason
score, prostate cancer can be staged by a TNM classification system [13]. This is a method
adapted from the American Joint Committee on Cancer (AJCC), where each letter
classification (T, N and M) denotes a location of disease metastasis. Each letter group has
sub-classifications which describe the extent of cancer growth in that location. The Tcategory refers to the tumour within the prostate gland, and its sub-classification describes
the size and extent of the primary tumour [13]. The N-category reflects the state of any
regional lymph nodes. Specifically, whether cancer cells have spread to the hypogastric,
obturator, internal iliac, external iliac, and sacral lymph nodes [13]. The M-category
identifies any metastases to distant sites in the body. The most common sites of metastases
are the bone, lymph nodes, lungs and liver [13]. The specific lymph nodes which most
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commonly harbour metastases are the para-aortic, common iliac, inguinal, supraclavicular,
scalene, and cervical. Table 1 below describes the subcategories of each classification.
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Table 1-1. TNM classification of prostate cancer. Table adapted from the
classifications outlined in National Comprehensive Cancer Network Guidelines for
Patients, Prostate Cancer, Version 1.2016 [13].

T1

Any tumours cannot be felt by DRE or seen with
imaging. These tumour types are diagnosed with
abnormal blood PSA levels.

T2

Tumours can be felt by a physician during DRE and are
visible with imaging. T2 score defines growth of tumour
cells that are confined to prostate gland.

T3

Tumour cells are present beyond the prostate gland. Cells
have reached surrounding connective tissue, seminal
vesicles or the neck of the bladder.

T4

Tumour cells have invaded other tissue types and may be
fixed onto these other tissues. Nearby tissue includes:
rectum, bladder, external sphincter, pelvic wall, and
surrounding muscles.

NX

It is unknown if cancer has spread to lymph nodes.

N0

No cancer found in nearby lymph nodes.

N1

Cancer has spread to nearby lymph nodes.

MX

No knowledge if cancer has spread to distant sites.

M0

No cancer growth in distant sites.

M1

Tumour cells have invaded distant sites.

T-Category

N-Category

M-Category
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1.2.4

Prostate Cancer Treatment and Overtreatment
For patients diagnosed with prostate cancer, many different treatment options are

available to these men. A panel review in 1995 by the American Urological Association
outlined that patient preferences should guide treatment decision making [36]. This
decision is difficult for patients, as men are given the option to choose either active
surveillance (AS) or immediate, more invasive treatment interventions. Active surveillance
is an observational strategy that allows patients to delay, or possibly avoid altogether,
therapeutic treatment measures. This is done without threatening the patients long-term
cancer-specific survival [37, 38]. Commonly, patients recommended for AS have been
characterized to have lower-risk, or clinically insignificant, PCa in biopsy cores. Clinically
insignificant disease is defined as limited volumes of cancer, characterized as Gleason
score ≤ 6, found on less than 3 of the 12 cores extracted. Additionally, this cancer must
have less than 50% involvement in any of the 12 cores. In AS, men visit their physician for
bi-annual (every 6 months) PSA blood tests and an annual DRE. Additionally, biopsy is
performed on these patients every 12 months to help further characterize the stage of the
lesions. In some healthcare systems, depending on the country each man lives in and access
to resources based on region of residence, multi-parametric-MRI (mpMRI) examinations
are included in AS protocols. There is concern with this technique, as it has been suggested
that AS only delays the inevitable (radical intervention) and potentially results in patients
missing the therapeutic window for curing their disease. Therefore, men who are expected
to live more than 20 years post-diagnosis often may choose therapy regardless. This is
because within their life-expectancy time frame, their cancer may metastasize outside the
prostate. The lifetime costs of AS of prostate cancer, identified through a Canadian
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Healthcare associated costs assessment are approximately $18,500, including potential
delayed treatment [39]. It is estimated that active surveillance results in approximately 12.5
quality-of-life adjusted years for men who chose this option [39]. If men do choose
immediate intervention instead of active surveillance, radical prostatectomy (RP) is the
most frequently given prostate cancer treatment. Radical prostatectomy is a surgical
procedure that removes the whole prostate gland, seminal vesicles, and vas deferens [37].
There are different types of RP, including nerve-sparing and non-nerve-sparing. The choice
between these two techniques is largely dependent on the patient’s sexual function and the
characteristics of the cancer. As well, nerve sparing surgery has been seen to lower
instances of incontinence post-surgery. This procedure has obvious benefit to men with
stage T1 and T2 prostate cancer (tumour cells that are totally confined to the gland) as
removal of the gland ensures total elimination of the cancer. Another possible procedure
for men with PCa is interstitial prostate brachytherapy and external beam radiation therapy.
Brachytherapy treatment involves radiation where the radioactive source is within the
prostate gland. This can be in the form of radioactive seeds (low-dose radiation) or through
needles inserted into the prostate gland (high-dose radiation). External beam radiation
therapy is another option for men, with certain techniques such as intensity modulated
radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) being used to
maximize cancer cell radiation while limiting healthy tissue exposure. For men who choose
radical treatment, the estimated healthcare-associated costs have been calculated to range
from $24,000 to $30,000 depending on the type of treatment given [39]. Further, these men
enjoyed approximately 11 years of quality-of-life adjusted years, which was 1.5 years less
than AS [39]. For men who underwent prostatectomy, studies have identified that at three

18

years post-surgery, over 90% of these men experienced sexual dysfunction and over 50%
of them dealt with some level of incontinence [40].
Due to the persistent notion in our society that all cancer is lethal and must be
treated, there is a large psychological burden that is associated with men choosing active
surveillance over radical treatment. This leads to conservative decision making by both
clinicians and their patients about the optimal way to treat each man’s cancer.
Overdiagnosis is defined as patients receiving further treatment interventions, such as
radical prostatectomy, and brachytherapy, who would be more appropriately treated with
active surveillance. Up to 80% of men who are screened with the PSA blood test, and are
detected to have prostate cancer, are over-diagnosed and subsequently overtreated [41].
Improved patient acceptance of AS protocols is one of the ways to combat this problem.
Accurate characterization of low- and high-risk prostate cancer can reduce overtreatment
of men with low-risk disease. It is estimated that improved compliance of patients for AS
would save the Canadian health care system $100 million per annual cohort of men
diagnosed with PCa. On a per patient basis, AS saves anywhere from $6,000 to $12,000
compared to treatment, while providing more quality-of-life adjusted years for patients
[39]. It stands to reason that better imaging tools for lesion characterization throughout the
entire gland would improve risk stratification. This in turn, would bolster patient and
physician confidence in surveillance, reducing overtreatment of this disease.
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1.3 The Sodium Ion and Tumour Metabolism
This section provides background information about the process and transporters
involved in sodium ion flux in cells. Additionally, it will touch on the metabolic processes
of both healthy tissue and cancer cells. These pathways have downstream effects on the
concentration of sodium ions in the tumour cell environment.

1.3.1

Sodium Ion Flux in Cells
The sodium ion is involved in many active cellular processes in the body including:

muscular contraction and conduction of nerve impulses. In tissue, there are two different
sites where sodium ions can reside: the intracellular space and the extracellular matrix. The
sodium-hydrogen (Na+/H+) antiport (NHE1) is a membrane-bound protein which is
involved in sodium movement across the cell membrane. This exchanger influxes sodium
ions into cells, and its activity is balanced by a sodium-potassium (Na+/K+) ATPase
activity, which drives sodium ion efflux into the extracellular matrix. These transporters
help cells maintain sodium homeostasis. NHE1 exchanges an intracellular H+ ion for an
extracellular Na+ ion with a 1:1 ratio. This exchange is driven by cells’ innate need to
maintain an optimal intracellular hydrogen ion concentration. When this concentration
fluctuates too high or too low, stresses are felt by the cell. Specifically, this influences the
intracellular pH. Therefore, cells have adapted efficient mechanisms to control the
intracellular H+ ion concentration. The sodium-hydrogen antiporters are found in
abundance across the cytoplasmic membranes of eukaryotic cells and the intracellular
organelles. The function of NHE1 is regulated by sensitive indicators that sense when the
cell requires its activity. Tissue sodium concentration (TSC) is a weighted average of the
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intra- and extracellular sodium ion concentrations in tissue. This weighted average is based
upon the relative compartmental sizes (volume) of the intracellular space and extracellular
matrix. Since sodium is a common product of cellular processes, TSC measurements are
likely to be sensitive indicators of changes in cellular function linked to disease.

1.3.2

Metabolic Activity in Healthy and Tumour Cells
Humans are multicellular organisms that are made up of highly evolved cells. These

cells compose tissues and have adapted very complex signaling pathways which allow us
to exist, grow, heal, and reproduce. One of these complex pathways is the regulation of
metabolism. For cells, there are two main types of metabolism. When stimulated by growth
factors, cells will undergo proliferative metabolism and focus on generating cellular
biomass which includes carbon, nitrogen, and excess energy. These cellular biomass
materials are the building blocks needed to divide and reproduce a new, viable cell.
However, most of the time, cells are not stimulated by growth factors, and therefore they
undertake differentiated cell metabolism. In full, differentiated metabolism turns sugar
molecules (glucose), into cellular energy (adenosine 5’-triphosphate (ATP)), to support the
cell’s energetic needs to perform its function in tissue. The first steps of this process involve
cytoplasmic glycolysis. This can be done with or without the presence of oxygen (aerobic
and anaerobic conditions, respectively). For each glucose molecule undergoing glycolysis,
two pyruvate molecules, two protons (H+), two ATP are produced. After this, the products
of glycolysis are pushed into one of two metabolic sub-categories based on the availability
of oxygen in the tissue environment. When oxygen is present in healthy tissue, pyruvate is
shunted into the mitochondria for admittance into the tricarboxylic acid (TCA) cycle (this
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is also known as the Krebs or Citric acid cycle). After this, the TCA cycle products are sent
to the electron transport chain (ETC), where ATP is produced with very high yield (~ 36
mol ATP/mol glucose). This pathway maximizes energy output per glucose molecule,
while also minimizing the production of lactate. This whole pathway is collectively known
as oxidative phosphorylation. In anaerobic conditions, the cells proceed with repeated
glycolysis, a pathway which has a much lower ATP yield per sugar molecule (~ 2 mol
ATP/mol glucose).
There are significant differences in the production of energy in tumour cells
compared with healthy cells. Tumour cells often rely on increased rates of glycolysis for
energy production regardless of the presence of oxygen, in what has been called “aerobic
glycolysis” [42]. More commonly, these whole-scale metabolic changes in tumour tissue
are referred to as the Warburg Effect. The phenomenon was first described by Dr. Otto
Heinrich Warburg in 1924 [43]. He originally hypothesized that defective mitochondria
caused this altered metabolism [44]; however, future work has suggested that this is not
the case and that other factors may be the cause [45]. It should be noted that aerobic
glycolysis is often a common pathway for healthy cells when they are exposed to scarce
resources. However, tumour tissue is not commonly found in such environments. Instead,
tumour tissue eschews the efficient energy production of oxidative phosphorylation to
ensure that they accumulate the necessary biomass required for proliferation. The reason
for this is that for proliferation, cells have metabolic needs that extend well beyond high
ATP levels; to produce viable daughter cells, the parent must accumulate biomass such as
nucleotides, amino acids, and lipids. Synthesis of amino acids and nucleotide requires
catabolism of reduced nicotinamide adenine dinucleotide phosphate (NADPH) and carbon
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molecules, making production of excess ATP less of a concern for these cells. A glucose
molecule, when broken down with oxidative phosphorylation produces approximately 36
ATP as noted above. However, the same glucose molecule can also be broken down via
aerobic glycolysis to form 2 ATP and 2 NADPH, which are then used for amino acid
synthesis. Additionally, glucose can be used as the carbon backbone in macromolecule
synthesis [42]. This highlights why the bulk concentration of glucose in proliferative
tumour cells are not streamlined for oxidative phosphorylation but instead are broken down
through aerobic glycolysis.

1.3.3

Implications on Tissue Sodium Concentration
Repeated aerobic glycolysis seen in tumour tissue leads to an increased lactate

concentration within cells. This reduces the intracellular pH within tumour cells, which
would normally lead to cell apoptosis. However, tumour cells avoid this outcome through
increased efflux of intracellular hydrogen ions. One of the ion-transport mechanisms
employed is sodium-hydrogen antiport (NHE1), mentioned above. This exchanger, which
pumps out intracellular hydrogen ions for extracellular sodium ions ([Na+]ex), increases the
intracellular sodium concentration ([Na+]in). Since [Na+]ex is kept relatively constant
through tissue perfusion [46], increased [Na+]in leads to an overall increase in tissue sodium
concentration (TSC). Additionally, it has been seen that intracellular acidification, as seen
in tumour tissue undergoing aerobic glycolysis, increases the cell membrane concentration
of NHE1 antiporters [47, 48]. This further facilitates increased [Na+]in in cancer cells.
Movement of hydrogen ions into the extracellular space also has supplementary benefits
for the cancer tissue. Extracellular acidification contributes to degradation of the
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extracellular matrix, making room for expansion of the tumour tissue [49]. Increased
intracellular sodium concentration has been seen to be a good measure of cell malignancy
and motility [47, 50]. TSC has been measured and compared to normal tissue in previous
studies of brain and breast cancer [51, 52]. These studies identified that cancer cells
exhibited a 50% increase in TSC. Additionally, low-grade Glioma has previously been
observed to exhibit a 100% increase in TSC when compared to healthy tissue [53].
Therefore, TSC may have utility to characterize prostate cancer stage, allowing for better
clinical decisions about patient treatment stratification based on lesion aggression.
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1.4

Introduction to 1H Magnetic Resonance Imaging

In this section, general background information is provided for standard magnetic
resonance imaging (MRI) of the hydrogen nuclei associated with water molecules.
Information will be provided about magnetization, nuclear spin, RF pulses, longitudinal
and transverse relaxation, gradient-echo sequences, T1- and T2-weighted imaging, and
multi-parametric MRI. Further detailed explanation of these topics can be found in several
references [54, 55].
MRI is a clinical diagnostic imaging modality that is known for production of images
with unrivaled soft tissue contrast. It has the capability to produce three-dimensional
imaging volumes that are extremely helpful for detection and differentiation of tissue
structures and changes in tissue associated with disease. MRI involves the use of a strong
homogenous magnetic field generated by superconducting magnets. The superconducting
magnet requires liquid helium as a cryogenic cooling fluid. MRI machines can vary in field
strength, and different magnet strengths are useful for both clinical and research
applications. The magnetic field strength of MR systems is quantified by the SI unit, Tesla
(T). Clinical MRI machines vary in the magnetic field strength, from low-field systems
(0.2 T) to high-field systems (7 T) but the most ubiquitous field strengths in the clinic are
1.5 and 3.0 T.

1.4.1

Nuclear Spins, Net Magnetization and RF Pulses
In standard MRI, the interaction between magnetic dipole moment of protons (1H)

and their environment is exploited to produce images. When these dipoles are in a
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magnetic-field-free environment, their orientation is random. However, when an external
magnetic field, B0, is applied, the nuclear magnetic dipole moments precess around the
field at a frequency known as the Larmor frequency ($% ). The Larmor equation is used to
calculate the Larmor frequency and is given by Equation 1.1:
$% = 2()*% .

Equation 1.1

In Equation 1.1, g is the gyromagnetic ratio (GMR). This is an intrinsic nuclear property,
measured in units of Hertz (Hz) per Tesla. For protons associated with water molecules,
the GMR is 42.576 ´ 106 Hz T-1. GMR is related to the strength of the magnetic dipole
moment of a nucleus. At rest, the distribution of magnetic dipoles in a sample are orientated
randomly, resulting in no net magnetization. However, when the volume to be imaged is
placed in the external magnetic field, the distribution of precessing dipoles will have a
“tendency” to align with B0 and therefore the sample’s dipoles will possess an overall net
alignment, or magnetization. This net magnetization is called ,% (Equation 1.2) and will
be aligned in the direction of the magnetic field. In MRI, it is standard practice to orient
the z-axis of a Cartesian coordinate system along the direction of the main magnetic field.
The sample magnetization, ,% ., is given by
,% = ,% . =

/0 1 2 ℏ2
456

*% ..

Equation 1.2

In Equation 1.2, ρ0 is defined as the number of protons per volume, ћ designates the reduced
Planck’s constant (ℎ/2(), k is the Boltzmann constant and T is the temperature of the
sample. The magnetization that is achievable at body temperature and clinical field strength
is small; this is a limiting factor in achieving high signal-to-noise ratio (SNR) in MRI. The
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human body concentration of hydrogen atoms in tissue is high, approximately 88 mol/L.
This helps facilitate in vivo imaging with protons. When we wish to detect the sample
magnetization, we first “tip” the net magnetization, ,% , away from its thermal equilibrium
position along B0 (Figure 1-2).

Figure 1-3. a) Net magnetization (!" ) is tipped away from the z-axis to an angle # by
a RF pulse. b) Relaxation of both transverse (Mt) and longitudinal (Mz) magnetization.
Transverse magnetization dephases to zero in the xy plane, governed by the time
constant T2. Longitudinal magnetization regrows along the z-axis, governed by the
time constant T1.
“Tipping” magnetization means to perturb it away from its equilibrium position, using a
transverse radio-frequency (RF) magnetic field. The transverse RF field is designated as
B1 and it oscillates at the Larmor frequency of the nuclei we wish to perturb. The RF field
is produced by an RF transmit coil. This RF field excites the net magnetization so that it
begins precession around the z-axis, at a specific angle :, called the flip angle (Figure 1-
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2). For example, if we were to apply a flip angle of 90° (Figure 1-2a), the ,% would be
excited entirely into the xy plane, where it would precess at the Larmor frequency.

1.4.2

Transverse Magnetization and Relaxation Time, T2
After an RF pulse perturbs the magnetization into the xy plane, we create transverse

magnetization, ,; (Figure 1-2b). Transverse magnetization can be further broken down
into Mx and My components, given by Equation 1.3.
,; < = ,= < > + ,@ < A.

Equation 1.3

The decay of this transverse magnetization to zero is governed by the transverse relaxation
time, T2. This decay of transverse magnetization is due to the interactions between the spins.
Their interactions result in a distribution of spins which precess at slightly different
frequencies, which eventually dephase causing decay of the net ,; to zero (Figure 1-2b).
Equation 1.4 describes the decay of Mt with time, governed by the time constant T2.
,; < = ,; (<)D E;/62 .

Equation 1.4

Dephasing of spins is additionally increased by the effects of inhomogeneities in the local
magnetic field. Field inhomogeneities can also be attributed to external sources such as
imperfect magnetic field shimming or magnetic susceptibility of certain tissues in
comparison to empty space (air). This is characterized by the effective spin-spin relaxation
time constant of tissues, designated as T2*. T2* is always shorter than T2.
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1.4.3

Longitudinal Magnetization and Relaxation Time, T1
Longitudinal magnetization, ,F , is described as the net magnetization that aligns

with the main magnetic field along the z-axis. This magnetization is parallel to B0 and is
known as the thermal equilibrium magnetization. After an RF pulse, the resulting tipping
of magnetization to the xy plane reduces the initial longitudinal magnetization. The
exponential regrowth of ,F is described by a longitudinal relaxation time constant, T1. The
T1 relaxation or spin-lattice relaxation time describes the loss of absorbed RF energy to the
environment around the spin system, also known as the lattice. Hence the name, spin-lattice
relaxation time. T1 relaxation time is always longer than the T2 relaxation time for a given
tissue type. Equation 1.5 describes the exponential, asymptotic regrowth of longitudinal
magnetization, governed by the T1 time constant:
,F = ,% 1 − D EI/6J .

1.4.4

Equation 1.5

MRI Signal Detection and RF Transmission
Signal in magnetic resonance imaging is a very important aspect of good imaging.

Signal-to-noise ratio allows us to quantify the quality of our imaging signal in relation to
noise level. Achievable SNR varies based on the nuclei we are imaging. Low SNR can be
an issue when physical limitations arise due to nuclei-dependent properties such as natural
abundance and in vivo concentration in tissue. However, we can improve SNR by
increasing the external magnetic field strength. This will increase the Larmor frequency
for excitation and detection and the amplitude of longitudinal magnetization (Equation 1.1
and Equation 1.2, respectively). Signal in MRI describes the detection of RF energy that is
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emitted by nuclei that was excited by the RF excitation pulse. RF transmit coils are tuned
to resonate at the Larmor frequency of the nuclei we wish to image and connected to an
appropriate RF source. After excitation, the transverse magnetization is detected by an
induced voltage at the Larmor frequency in the receive RF coil (or the same RF coil used
for excitation). Detected signal in MRI drops off very rapidly as the distance between the
tissue of interest and the detection RF coil increases. Therefore, these coils are typically
built to be positioned as close as possible to the volume of interest.

1.4.5

Gradient-echo sequences
Efficient use of transverse magnetization is key to produce images with high SNR.

To optimize usage of this magnetization, the dephased spins are refocused using an “echo”.
In gradient-echo sequences, rephasing of dephased transverse magnetization is induced by
applying a refocusing magnetic gradient pulse during standard transverse magnetization
decay. This can be done multiple times, producing multiple “echoes” per RF excitation.
The time between excitation of the magnetization using the RF pulse and formation of the
echo is called the time-to-echo (TE) while the time between each RF excitation pulse is the
time-to-repetition (TR). Gradient-echo sequences and spin-echo sequences (using RF
refocussing instead of gradient refocusing) are the most frequently used pulse sequences
in MR because of their versatility and simplicity.

1.4.6

T1-weighted and T2-weighted imaging
T1 and T2 values are inherent properties of tissues, which we can use to enhance

image contrast between different tissues. By selecting a pulse sequence, such as a spin-
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echo or gradient-echo, imaging data can be acquired with a T1- or T2-weighting. T1weighting is achieved by choosing imaging parameters to have a short TE and TR values
on the order of the T1 value of the tissue of interest. Contrast on T1 images can be enhanced
by addition of a paramagnetic contrast agent, such as chelated gadolinium. The effect on
image quality seen by contrast agents owes to the fact that they increase the rate of spinlattice relaxation of protons in surrounding tissue allowing for increased local signal in a
T1-weighted image. T2-weighting is achieved by specifying imaging parameters to have a
TE on the order of the T2 value of the tissue and a long TR. In T2-weighted imaging, fluids
appear brighter within the images. This is because fluids have longer T2 values than tissues,
leading to increased signal.

1.4.7

Multi-parametric Magnetic Resonance Imaging
Multi-parametric magnetic resonance imaging (mpMRI) is seeing increased

frequency of use in the clinic. This suite of MR imaging contrasts may include acquisition
of some or all of: T1- and T2-weighted imaging, diffusion weighted imaging (DWI), and
dynamic contrast-enhanced (DCE) imaging.
Diffusion weighted imaging is an imaging technique based on measurement of
random Brownian water diffusion in tissues [56]. This motion is isotropic and is driven by
thermal energy of water molecules. Signal in these images is measured from four sources,
with diffusion of water existing in the extracellular space being the major contributor. The
speed at which water molecules diffuse is primarily influenced by the ratio of the cellular
volume (how many cells occupy a given area) and the volume of the extracellular space.
Diffusion weighted images are inherently T2-weighted. Apparent diffusion coefficient
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(ADC) values, units of mm2/second, can be calculated from DW images using Equation
1.6.

KLM =

1 Q
ln .
N Q%

Equation 1.6

Here, b-values describe the strength and timing of the gradients used to generate these
images, S and S0 are the signal intensities at specific b values chosen based on the tissue
being imaged. Approximately 35% of all clinical MRI examinations are acquired using a
contrast agent [57]. Contrast agents are pharmaceutical drugs that affect the magnetic
environment of protons in the vicinity where they are taken up. Paramagnetic contrast
agents, such as gadolinium (Gd), accelerates the T1 relaxation of nearby tissue, resulting in
positive signal enhancement. Superparamagnetic contrast agents such as iron oxide,
predominantly increase T2 relaxation rates, which leads to negative signal enhancement
[58]. These contrast agents can be engineered for selective binding to a specific disease or
protein producing specific and significant signal enhancement for that target [57].
In the detection of prostate cancer, sensitivity and specificity of T2-weighted
imaging for detection of prostate cancer has been seen to be 62% and 77%, respectively.
Diffusion weighted imaging has been measured to have a sensitivity and specificity of 69%
and 89%, respectively. Previous works have demonstrated that dynamic contrast enhanced
imaging had a sensitivity and specificity of 43-53% and 83%, respectively. When
combining T2-weighted imaging, DWI, and DCE-MRI, pooled sensitivity and specificity
resulted in 74% and 88%, respectively [59].
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1.5

Sodium Magnetic Resonance Imaging

Over the past 20 years, imaging research has investigated many cellular metabolites
and nuclei such as sodium as endogenous imaging biomarkers allowing for earlier
detection of disease states, including cancer [51, 53, 60]. In section 1.3, detailed
explanation about the flux of sodium ions in both healthy and tumour tissue has been
discussed. This highlights the importance of sodium detection and use of sodium imaging
in the clinical setting as it has been seen to be a biomarker of proliferation in cancerous
cells. However, sodium magnetic resonance imaging (sodium-MRI or

23

Na-MRI), is

associated with many challenges due to the composition of tissue and the nuclear properties
of the molecule. This section will describe background information regarding the
difficulties of sodium-MR imaging and particular procedures that have been employed to
facilitate quantification and detection of sodium.

1.5.1

Difficulties of Sodium-MRI
Sodium-MR imaging is a technique used to quantify the concentration of sodium

in tissues. One of the basic properties required for MR imaging is the property of a nonzero spin-value (magnetic dipole moment) for a nucleus. Sodium possesses a nuclear spin
R

of and 100% of the nuclei exist naturally in this state (as 23Na). However, certain hurdles
S

make sodium-MRI challenging. These include the low tissue concentration of 23Na ions in
R

the body, its low gyromagnetic ratio (11.262 MHz T-1) and the nuclear spin. Depending
S

on assumptions related to noise during detection, SNR in MRI is approximately
proportional to GMR5/2. The average intracellular sodium concentration in humans is
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approximately 10-15 mmol/L, while the extracellular concentration is approximately 140
mmol/L. A weighted average, based on the volumes of each cellular space, results in a
whole-body healthy tissue sodium concentration (TSC) of ~ 90 mmol/L. In contrast, the
concentration of water-associated protons is approximately 80 mol/L in tissues, which is a
factor of 103 higher than that of sodium nuclei.
Sodium nuclei possess an intrinsic spin of

R
S

and therefore exhibit an electric

quadrupolar moment in addition to a magnetic dipole moment. This additional nuclear
moment leads to bi-exponential T2 relaxation of sodium. Bi-exponential decay describes a
magnetization decay with two distinct components: a short (T2,
component [61]. T2,

fast

fast)

is ~ 0.5-5 milliseconds (ms), while T2,

Acquisition of signal from both T2,

slow

and T2,

fast

and long (T2,

slow

slow)

is ~ 15-30 ms.

decay components is necessary for

preserving maximum SNR and beneficial for quantifying TSC. To facilitate this, the MRI
pulse sequence is optimized for short TEs [62]. When sodium nuclei are exposed to an
R

external magnetic field, the spin of sodium leads to four distinct energy levels (Zeeman
S

R T

T

R

S S

S

S

energies). These energy levels are: , , − , − and transitions between these levels alters
the observed relative amplitudes of T2, fast and T2, slow relaxation.

1.5.2

Quantifying Sodium Concentration with Sodium-MRI
To facilitate in vivo sodium imaging of tissue in the body, custom imaging hardware

is needed to perform RF excitation and detection of sodium nuclei at their specific Larmor
frequency [63]. This hardware must be highly optimized and can be paired with very short
echo times in pulse sequences (mentioned in previous section) to maximize possible SNR.
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In addition, the sodium RF hardware should not significantly interfere with proton imaging
used to acquire morphological images for image registration of regional TSC, mpMRI and
histopathology data determined after prostatectomy.
When imaging with sodium-MRI, we require the use of phantoms to quantify the
sodium signal. First, assessment of the sensitivity profile of the RF coils is necessary. This
is typically done using a large saline bath with a sodium concentration between
100-150 mmol/L. Following this, a procedure described by Axel et al. (1987) allows for
normalization of the sodium signal based on the location of the voxel relative to the receive
coil [64]. In the housing of the receive RF coil itself, reference phantoms are incorporated
with known concentrations ranging from 20-150 mmol/L for quantification of absolute
tissue sodium concentrations in the voxel of interest.
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1.6

Objectives, Hypothesis and Goals

The objective of this thesis was to investigate the relationship between in vivo tissue
sodium concentration and prostate cancer tumour aggression. Tissue sodium concentration
was assessed in men with biopsy-proven prostate cancer using sodium-MR. After
prostatectomy, whole-mount histopathology sections of the prostate were examined by an
expert and lesions were identified by contours and assigned a Gleason grade for
aggressiveness. Co-registration of MRI imaging data (TSC, T2-weighted contrast and ADC
values) with the histopathology allowed for accurate comparison of lesions to imaging data.
We hypothesized that the endogenous tissue sodium concentration measured in prostate
cancer patients would have a significant relationship with histological Gleason score.
Specifically, we hypothesized that TSC values would have monotonic, increasing trend
with Gleason grade, leading to accurate staging of lesions into low- and high-risk
categories based on the acquired TSC data.
The goal of this work was to identify the utility of using TSC as a component of a noninvasive imaging assay. In this, sodium-MRI would be employed with mpMRI to aid in
prostate cancer lesion detection and subsequent characterization of that lesion’s grade in
vivo. This would give men with low-grade prostate cancer more confidence to choose
active surveillance instead of treatment, reducing the frequency of overtreatment in our
healthcare system.
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Characterization of Clinical Human Prostate Cancer
Lesions Using 3.0-T Sodium-MRI Registered to
Gleason-Graded Whole-Mount Histopathology
Nolan C. Broeke, Justin Peterson, Joseph Lee, Peter Martin, Adam Farag,
Jose Gomez-Lemus, Madeleine Moussa, Mena Gaed, Joseph Chin, Stephen
Pautler, Aaron Ward, Glenn Bauman, Robert Bartha, Timothy J. Scholl

2.1 Abstract
Overtreatment of prostate cancer is a significant problem in the health care of men.
Development of non-invasive imaging tools for improved characterization of prostate
lesions can reduce overtreatment. We have previously built custom sodium-MRI hardware
to image and quantify tissue sodium concentration (TSC) in the human prostate from
sodium-MRI. In this study, we have evaluated sodium-MRI and mpMRI data (including
diffusion-weighted and T2-weighted imaging) from a patient cohort of ten men with
biopsy-proven prostate cancer. All imaging data were co-registered to Gleason-graded
post-prostatectomy histology, as the standard for prostate cancer lesion characterization.
TSC and T2 data were assessed using percent changes from healthy tissue of the same
patient (DTSC, DT2). Significant changes in DTSC, ADC values and DT2 were observed
between Gleason scores in averaged cohort data (p < 0.05). Evaluation of the correlation
of DTSC, ADC, and DT2 data sets with Gleason scoring revealed that only the correlation
between DTSC and Gleason score was statistically significant (rs = 0.791, p < 0.01),
whereas the correlations of ADC and DT2 with Gleason score were not (rs = -0.306, p =
0.079 and rs = -0.069, p = 0.699, respectively). In addition, all individual patients showed
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an increasing trend of DTSC with Gleason score. The results of this study suggest that TSC
assessed by sodium-MRI has utility as a “non-invasive imaging assay” to accurately
characterize prostate cancer lesions. Sodium-MRI can provide useful complementary
information to mpMRI, ultimately leading to increased confidence of men with low-risk
disease to opt for active surveillance instead of treatment.
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2.2 Introduction
One in seven men will develop prostate cancer (PCa) in their lifetime, making it
the most common non-cutaneous malignancy in males [1]. However, overdiagnosis of
clinically insignificant disease has been a concern since the introduction of the prostatespecific antigen (PSA) screening test [2-4]. Overdiagnosis has been shown to negatively
affect patient quality of life and increase the healthcare costs for society [5]. For men with
suspected prostate cancer, a standard approach involves a transrectal ultrasound (TRUS)guided biopsy to extract 12 cores [6] for histological Gleason scoring. The current system
for grading PCa is the Gleason Scoring System. The combination of the primary and
secondary cancer grades present is inherently related to tumour aggression; making the
Gleason score the strongest prognostic and predictive factor for the disease [7-9]. However,
biopsy only samples approximately 0.5% of the prostate, which carries a 30-40% risk of
under sampling clinically significant lesions [10-12]. Therefore, the use of non-surgical
imaging-based methods to accurately discriminate between low- and high-grade lesions
would be useful to reduce repeated negative biopsies, to place patients in the proper
treatment streams and to surveil low-risk cancer. This, in turn will optimize patient
outcomes and the use of health care resources. Currently, multi-parametric magnetic
resonance imaging (mpMRI) contrasts such as T2-weighted, diffusion-weighted magnetic
resonance imaging (DWI), and dynamic contrast enhanced MRI (DCE-MRI) aid
physicians in PCa lesion detection [13-15]. Diffusion-weighted imaging signal intensity is
based on measurement of the Brownian motion of water molecules in a voxel [16]. Inverse
correlations between apparent diffusion coefficient (ADC) signal intensity and cell count
in tumours were shown by Surov et al. [17]. The strength of these correlations was seen to
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be dependent on the location of the cancer tissue, with only moderate inverse correlations
recorded in prostatic cancer [17]. T2-weighted prostate MRI produces anatomical images
with high spatial-resolution and it allows for precise differentiation of the different zones
of this gland. On T2-weighted images of the prostate, lesions in the peripheral zone
typically show a hypo-intense signal compared to healthy tissue [14]. The degree of these
differences can vary with Gleason score. However, regions of lower signal do not
necessarily represent malignancies. Prostate lesions arising from scars, atrophy,
hyperplasia, chronic prostatitis, and post-biopsy hemorrhage have been shown to also
exhibit low signal intensity on T2-weighted images [18].
These techniques provide high spatial resolution, but their specificity is often
insufficient to localize malignant lesions and confidently assign tumour grades to these
foci. Thus, there is a need for new imaging biomarkers to provide complementary
information about the location and grade of intraprostatic cancer. Tissue sodium
concentration (TSC) has been shown to be a sensitive indicator of cell integrity and energy
metabolism [19-21]. The link between increased activity of a sodium-proton (Na+/H+)
antiport [22, 23] and sodium-potassium (Na+/K+) ATPase [19, 24] and tumour malignancy
has been well studied. TSC measured by sodium (23Na) MRI can provide regional
information about intracellular and extracellular changes within tissue. While TSC has
been examined in brain and breast cancer [21, 25, 26], TSC has not yet been compared to
tumour grade in human PCa. Our lab has previously developed

23

Na imaging hardware

comprised of a transmit-only asymmetrical birdcage coil and a receive-only endorectal
coil, providing sufficient sensitivity to image endogenous sodium throughout the human
prostate [27]. In this research study, mpMRI and sodium-MRI data were collected from
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men with biopsy-proven prostate cancer prior to prostatectomy. These imaging data were
subsequently registered to graded PCa lesions identified on whole-mount histopathological
sections through a validated registration pipeline [28]. Tissue sodium concentration, ADC
values, and T2-weighted signal intensity were compared and correlated with histological
tumour grade to assess the utility of TSC for improved characterization of prostate lesions.
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2.3 Methodology
2.3.1

Patients
Ten male patients (aged 63±5) (Table 1) selected through previous biopsy to have

PCa of Gleason score 7 or less were recruited between 2013 and 2016 in conjunction with
a multi-modality, image-guided prostate cancer study (IGPC-2) [28]. This selection
process intentionally targeted a patient population including low to intermediate risk
groups, where additional characterization of tumour aggression would be particularly
useful for risk stratification decisions where mpMRI provides less reliable guidance. In
addition to standard exclusion criteria for MR studies (implanted devices etc.), men were
excluded from this study if they had prior therapy for PCa, use of 5-alpa reductase
inhibitors within 6 months of the start of the study, a prostate volume greater than 68 cc,
allergies to contrast agents and other administered agents, insufficient renal function, and
a residual bladder volume greater than 150 mL. Patients were instructed to drink 30 mL of
milk of magnesia the night before the MR exam and to fast 12 hours prior to the exam.
Sodium-MRI was performed in combination with mpMRI, including the following
contrasts: diffusion-weighted, T2-weighted, and post-Gadolinium T1-weighted imaging,
however DCE was not included in the data analysis. Ex vivo imaging of the prostatectomy
specimens included T1- and T2-weighted imaging.

Patient 1
64

Patient 2
53

Patient 3
66

Patient 4
64

Patient 5

66

Patient 6

68

Patient 7

59

Patient 8

57

Patient 9

66

Patient 10

47

65

3

3

6

4.16

4

37

3

4

7

cT2a

1.05

7

cT1c

48.32

3
4

22.6

3.67

7

cT1c

3
4

23

4.66

8

cT2b

4
3

57

25.49

7

cT2a

4

4

39

4.33

7

cT1c

3

4

65

6.13

7

cT2b

3

4
25

4.22

7
cT1c

3

4
30

5.05

7
cT2c

3

Secondary Pattern
45

14.96

Table 2-1. Clinical data for the ten patients analyzed in this study.
Category
Age
Pre-Treatment Procedures
Pre-biopsy PSA (ng/mL)

Overall Gleason Score
cT2c

Primary Pattern

Prostate Volume (cc)
Clinical T-Stage

Secondary Pattern

Primary Pattern

Residual Bladder Volume (mL)

Urea (mmol/L)

eGFR (mL/min/1.73m2)

Creatinine (µmol/L)

5

4

3

78

5.1

95

76

7

none

4

3

224

3.9

64
116

7

none

4

3

165

6.9

79

92

7

5

4

3

49

5.2

78

90

7

none

3

4

20

9.2

85

84

7
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2.3.2

In Vivo multi-parametric MR Imaging
All magnetic resonance imaging data for this study were acquired at a field strength

of 3 T (General Electric Healthcare Discovery MR750 3.0 T, Milwaukee, WI, USA). Highresolution T2-weighted images (TE: 162 ms, TR: 2000 ms, Field of view (FOV): 140 × 140
mm, voxel size: 0.44 × 0.73 × 1.4 mm, flip angle: 90˚) were acquired using a 3D Cube
sequence, and the standard inflatable 1H endorectal (ER) coil. This image set was used for
registration of sodium images to histopathology. Apparent diffusion coefficient (ADC)
maps were obtained using a 2D Spin-Echo sequence, the inflatable 1H endorectal coil, and
the following parameters: TE: 68.1 ms, TR: 5600 ms, FOV: 140 × 140 mm, voxel size: 1.1
× 0.55 × 3.6 mm, flip angleK 90˚, and b-values of 100 and 800 s/mm2.

2.3.3

Sodium Imaging
Sodium imaging was performed using a bespoke endorectal receive-only

radiofrequency (RF) coil and an asymmetric transmit-only birdcage RF coil [27]. A topical
anesthetic, Xylocaine (2%) was applied to the patient prior to insertion of the ER coil.
Following insertion of the 23Na ER coil a set of 1H, axial T2-weighted images were initially
acquired using a 2D Fast Spin-Echo sequence (TE: 139.2 ms, TR: 5300 ms, FOV: 140 ×
140 mm, voxel size: 1.09 × 1.09 × 3 mm, and flip angle: 90˚) to provide morphological
context for the sodium images. This enabled accurate registration of the sodium images to
the high-resolution T2-weighted image set. 1H imaging with the 23Na hardware was possible
because of the unshielded design of the transmit-only RF coil, along with proper detuning
of the receive-only ER coil. Sodium images were then acquired using a broad-banded 3D
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Fast Gradient-Recalled-Echo sequence with the following parameters: TE: 1.5 ms, TR: 80
ms, FOV: 140 × 140 mm, voxel size: 4.4 × 4.4 × 6 mm, and flip angle: 85˚. Three
calibration vials containing 30, 90, and 150 mmol/L of sodium chloride (NaCl) solutions
were incorporated into the rigid

23

Na ER coil. These solutions were used to scale the

sodium signal from the prostate tissues to absolute concentrations per Farag et al. [27].
Sodium images were normalized to the sensitivity profile of the

23

Na ER surface coil,

acquired in a separate measurement in a procedure described by Axel et al. [29].

2.3.4

Ex Vivo Imaging
Following radical prostatectomy, prostate specimens were encased in a syringe of

Christo-Lube MCG 1046, an MR-invisible fluorinated lubricant, to minimize magnetic
susceptibility artifacts at the tissue-prostate boundary. The specimens were then imaged on
the same 3 Tesla scanner used for in vivo imaging. Both T1-weighted (TE: 2.34 ms, TR:
6.41, FOV: 140 × 140 mm, voxel size: 0.73 × 0.55 × 0.6 mm, flip angle: 15˚) and T2weighted (TE: 114 ms, TR: 2000 ms, FOV: 140 × 140 mm, voxel size: 0.73 × 0.44 × 0.6
mm, and flip angle: 90˚) images were obtained using a 3D Spoiled Gradient-Recalled-Echo
and a 3D Cube sequence, respectively.

2.3.5

Whole-Mount Pathology
Dyed cotton threads, treated with paramagnetic contrast agent were used as MRI-

visible fiducial prostate markers, which are also visible under microscopic examination.
Excised prostate specimens were pierced with three cotton threads through the prostate and
seven threads on the surface as fiducial markers. The prostate midglands were then sliced
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into ~4-mm transverse sections before paraffin embedding, leaving enough of the apex and
base to be sliced in the sagittal plane for routine pathology analysis. Using a microtome, a
4-µm slice was obtained from each section and stained with Haematoxylin and Eosin
(H&E). The slides were then scanned at high resolution (0.5-µm isotropic resolution, 24bit colour) using a bright-field slide scanner (ScanScope GL; Aperio Technologies, Vista,
CA, USA) and subsequently contoured for Gleason score by a pathology assistant
supervised by a genitourinary pathologist [28, 30].

Figure 2-1. Registration pipeline for all imaging data with Gleason contours overlaid.
Whole-mount histopathology (a) and the sodium-MR image (b) are registered to the
T2-weighted ex vivo (c) and the lower resolution T2-weighted in vivo images (e)
respectively. The ex and in vivo images are individually registered to the high
resolution T2-weighted in vivo image (d). Gleason contour legends are shown in the
upper middle panel.
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2.3.6

Registration
Co-registration of image data was necessary due to the deformation of the tissue,

caused by differing geometries (rigid vs. inflatable) of the ER probes and the uncompressed
nature of the ex vivo tissue. Comparison of the contoured histology to sodium-MRI data,
ADC maps and T2-weighted contrast was achieved through a previously reported
registration pipeline [28]. Figure 1 outlines all the image contrasts involved and their
position along the registration pipeline. ADC is not included in the pipeline figure as it is
inherently registered to the high resolution T2-weighted images. All manual registration
was performed using 3D Slicer (version 4.3.1) with a non-rigid, interactive thin-plate spline
(TPS) extension [31]. Registration involved positioning of approximately 40 fiducial
points on physiologically relevant ROI’s, such as benign prostatic hyperplasia and cystic
spaces, in the two image volumes being co-registered [28]. After fiducial points were
finalized, an input and reference volume were chosen, and the input volume was deformed
to fit the reference volume according to the fiducial points chosen. The measured error for
3D histopathology reconstruction is 0.7 mm, with an overall ex vivo MRI-histopathology
co-registration error of ~ 1.5 mm [28], resulting in a total ix vivo MRI-histopathology coregistration error of ~ 3 mm.

2.3.7

Statistical Analysis
The histology contour masks outlined on each slice for each Gleason grade were

overlaid onto co-registered TSC data, ADC maps and T2 images to determine how the data
obtained from each image set compares to identified regions of Gleason score. Distinct
identified regions are classified in two ways: regions of Gleason pattern completely
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encapsulated by either healthy tissue or another Gleason score. Areas of patchy Gleason
patterning were segmented into 4-mm2 areas that contained only one Gleason score. TSC,
ADC and T2-measurements were collected from four Gleason grades, prostatic
intraepithelial neoplasia (PIN), and healthy peripheral zone (PZ) tissue. Healthy peripheral
zone tissue is designated as the remaining area of the peripheral zone on the histology slides
that has not been identified as cancerous by Gleason grading. The areas (mm2) of Gleason
contour coverage on whole-mount histology sections are displayed in Table 2. ADC data
are presented as absolute ADC values, while TSC and T2 data are presented as percent
changes in TSC (DTSC) and T2-contrast (DT2). These values are calculated using equations
2.1 and 2.2, respectively.

DTSC = 100% ×

D+< = 100% ×

(+,-./0123 − +,-5/6789: )
+,-5/6789:
+< ./0123 − +< 5/6789:
+< 5/6789:

Equation 2.1

Equation 2.2

Using percent change of TSC and T2-signal rather than absolute signal allows for more
direct observation of changes due to changes in lesion stage. Resting in vivo sodium levels
can be different between individual, dependent on metabolic activity and perfusion. The
can result in inter-patient differences in baseline tissue sodium concentrations. Our
measurements assess how TSC and T2-contrast change from an individual’s baseline levels
with increasing Gleason score. All data were imported into GraphPad Prism (GraphPad
Software, La Jolla, CA, USA) to test for significant differences in DTSC, ADC and DT2
values in relation to Gleason score for both individual patients and averaged data.
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Differences were tested using either a one-way analysis of variance (ANOVA) and a
follow-up Tukey test or an unpaired t-test, depending on the number of Gleason grades
present in each individual. For these statistical tests, the n used was equal to the number of
identified voxels. SPSS statistical software version 20.0.0 (IBM Co., Armonk, NY, USA)
was then used to perform a Spearman’s non-parametric ranked correlation; testing the
strength of the association between DTSC, ADC and DT2 values and Gleason score. For
this test, the n-value represents the number of patients that had each Gleason score. A
Pearson’s parametric non-ranked correlation was performed between DTSC, ADC and DT2
data to assess the associations between these values. Error bars on individual patient graphs
are standard error of the mean. Error bars on patient cohort graphs represent one standard
deviation.
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2.4 Results
We analyzed data from ten patients, all with biopsy proven PCa. Clinically relevant
patient data is given in Table 2-1. In the prostatectomy specimens acquired from the 10
cases, 564 distinct identified regions of Gleason graded cancer were found in the peripheral
zone based on manual segmentations. The distribution of these identified regions on a per
patient basis is shown in Figure 2-2.

Figure 2-2. The number and distribution of identified regions of prostate cancer is
shown in each of the 10 patients. The identified regions were manually segmented on
accurately co-registered whole-mount histopathology using a method described in the
statistical analysis section.
The area of individual lesions measured for analysis ranged from 2.5 mm2 to 122 mm2 on
histological sections. All measurement data are displayed in Table 2-2. Across the ten
prostates analyzed, nine contained regions of PIN, ten showed Gleason 3, six contained
Gleason 3+4, four had Gleason 4+3 patterning, and six showed Gleason 4. Six patients had
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clinically significant lesions (> Gleason 7). One patient possessed a high pre-biopsy PSA
level and only one Gleason grade of cancer (Patient 6) and therefore was excluded from
individual statistical analysis but was included in calculation of the averaged data.
Individual patient data from each imaging contrast was collected and displayed in Table 22 and graphed in the supplementary information.

Case

Patient
1
Patient
2
Patient
3
Patient
4
Patient
5
Patient
6
Patient
7
Patient
8
Patient
9
Patient
10
Average

56

Table 2-2. Percent changes in TSC (DTSC), ADC values and percent changes in T2-signal (DT2) are shown for all 10 patients.

Data are displayed as DTSC, ADC or DT2 ± standard deviation. The size of the Gleason contour from which the imaging data
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Averaging all patient data showed a statistically significant increasing trend in
DTSC with respect to Gleason score. Furthermore, statistically significant increases in
DTSC within graded lesions were observable in the data from six of the nine patients
(p < 0.05). Data from a representative patient (Patient 5) is shown in Figure 2-3, where
significant differences were measured between all grades except between Gleason 3 and
3+4 (p < 0.01).

Figure 2-3. ∆TSC in relation to Gleason grade for a representative case (Patient 5)
from our 10-patient cohort. Error bars represent standard error of the mean.
Intermediate-risk disease (Gleason 7) is frequently classified into treatment
schemes based on the predominant identified Gleason pattern. Many clinicians will
recommend patients with cancer < Gleason grade 6 (3+3) for active surveillance (AS).
Subsequently, men with Gleason scores of 7 and above are candidates for treatment [9, 32].
We report that DTSC increased significantly between Gleason 3 and 3+4 in five of the six
patients who possessed lesions greater than Gleason 3+4. Graphs of DTSC and Gleason
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grade from all ten patients are provided in Supplemental Figure 1. DTSC patient cohort
data were collected and plotted together in Figure 2-4a. These data were correlated with
Gleason score using a Spearman’s correlation. An rs value of 0.791 was found showing a
significant positive correlation (p < 0.01) (Figure 2-7). Weighted averages of DTSC were
calculated for each Gleason score (Figure 2-4b). These data showed a monotonic increase
in DTSC with Gleason score. Statistical analysis showed that all differences in average
DTSC values between Gleason grades were significant (p < 0.001). It was observed that
the differences in DTSC between adjacent Gleason grades becomes larger as identified
cancer increases in stage in averaged data.

Figure 2-4. ∆TSC in relation to Gleason score. A) Patient cohort data. Horizontal red
line indicates weighted average of all data points. Error bars represent standard
deviation. Value of n represents the number of patients that possessed a particular
Gleason score out of the cohort of 10. b) Weighted average of ∆TSC data, error bars
represent one standard deviation. The rs values shown represents the Spearman’s
correlation coefficient.
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ADC values were also compared to Gleason score. Individual patient data
possessed significant differences between Gleason grades in seven of nine datasets
(Supplemental Figure 2). However, a non-monotonic trend between ADC and Gleason
score was observed in both individual patients and cohort data (Figure 2-5a). A Spearman’s
correlation test was performed on patient cohort data, identifying a non-significant
correlation of ADC with Gleason score (rs = -0.306, p = 0.079) (Figure 2-7). Weighted
averages of ADC data were calculated from each Gleason score (Figure 2-5b). Nonmonotonic, significant differences in ADC values were observed between all the Gleason
grades (p < 0.05).

Figure 2-5. ADC measurements in relation to Gleason score. a) Patient cohort data.
Horizontal red line indicates weighted average of all data points. Error bars represent
standard deviation. Value of n represents the number of patients that possessed a
particular Gleason score out of the cohort of 10. b) Weighted average of ADC data,
error bars represent one standard deviation. The rs value shown represents the
Spearman’s correlation coefficient. ns denotes no significance.
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DT2-data were compared to Gleason score using the same percent change method
used with TSC data. Individual patient data possessed significant differences between
Gleason grades in seven of the nine datasets (Supplemental Figure 3). A Spearman’s
correlation was performed on patient cohort data (Figure 2-6a), showing a non-significant
correlation between DT2 and Gleason grade (rs = -0.069, p = 0.699) (Figure 2-7). Weighted
averages of DT2-data exhibited non-monotonic, significant differences between Gleason
scores (Figure 2-6b).

Figure 2-6. DT2 in relation to Gleason score. a) Patient cohort data. Horizontal red
line indicates weighted average of all data points. Error bars represent standard
deviation. Value of n represents the number of patients that possessed a particular
Gleason score out of the cohort of 10. b) Weighted average of DT2 data, error bars
represent one standard deviation. The rs value shown represents the Spearman’s
correlation coefficient. ns denotes no significance.
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Figure 2-7. Absolute values of Spearman’s non-parametric ranked correlation
coefficients for DTSC, ADC, and DT2 data. Correlations were performed between
imaging data and Gleason grade. No significance denoted by ns.
We tested the associations between all our imaging data using a Pearson correlation.
We observed a statistically significant correlation between ADC and DT2 data (r = 0.472,
p = 0.005). DTSC was not correlated with ADC or DT2 (r = 0.058, p = 0.371, and r = -0.158,
p = 0.745, respectively).
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2.5 Discussion
We report the first in vivo measurement of tissue sodium concentration in human
prostate cancer. In addition, this work also represents the first correlation of changes in
tissue sodium concentration acquired with sodium-MRI to histologically confirmed
Gleason grade using a validated image registration pipeline. Our data show a statistically
significant monotonic increase in DTSC with increasing Gleason score for individual
patients and cohort-averaged patient data. This provides preliminary evidence for the use
of sodium-MRI as a non-invasive approach to characterize prostate lesions.
Previously, we have demonstrated that TSC can be measured in the human prostate
with high signal-to-noise ratio [27]. The gold standard for prostate cancer diagnosis is an
invasive 12-core biopsy, sampling a small fraction of the volume of the entire prostate
gland. Uncertainty that arises after negative biopsies due to under sampling of potentially
aggressive lesions is a major concern for physicians when assigning men to active
surveillance. Low-risk, Gleason 6 cancer is the most common diagnosis after biopsy; this
grade rarely metastasizes and has a very small associated mortality. This study
demonstrates that sodium-MRI of the prostate could provide additional reliable
information to non-invasively characterize prostate lesions for risk stratification decisions.
Patients with lower-risk lesions could be confidently monitored with active surveillance,
which might include sodium-MRI, whereas patients in the high-risk category (> Gleason
7) would receive treatment as prescribed by the National Comprehensive Cancer
Network’s (NCCN) guidelines [33]. Gleason score 7 patients with low-volume grade 4
lesions (Gleason 3+4), who are sometimes excluded from an immediate treatment
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recommendation, would benefit from whole-gland lesion characterization by TSC
measurement [9]. More reliable non-invasive identification of biologically significant foci
in the gland may enable clinical decisions including targeted biopsy, focal therapy or focal
dose escalation strategies [34-38].
This study involved the development of advanced MRI hardware and a
comprehensive data analysis including 3D registration of whole-mount digital
histopathology to multiple mpMRI contrasts with a high degree of accuracy (~2 mm).
Accurate image registration is imperative to assure that the TSC data measured in a specific
ROI are being accurately associated with the Gleason contours on digital histology (see
Figure 1). Finally, the development of sensitive integrated TORO RF hardware for sodium
imaging was an important development for PCa research [27]. The current study shows
that DTSC increases with Gleason grade, and this trend was present both in individual data
sets and patient cohort data. This increasing trend showed a strong significant correlation
with Gleason score (p < 0.01), while data from ADC and DT2 did not show strong
correlations (Figure 7). While we are unable to associate the DTSC correlation with specific
cellular changes, it is likely due to cellular reorganization (volume changes) and increased
intracellular sodium concentration [21]. With increasing Gleason score, cellular density
increases, which leads to a decreased extracellular volume. Cancer cells have been shown
to exhibit an increased metabolism, which supplies the cell with enough energy to support
accelerated proliferation and enhanced motility [39]. The caveats of this increased
metabolism include an upregulation of the sodium-proton (Na+/H+) antiport [22, 23] and
inhibition of a sodium-potassium (Na+/K+-ATPase) pump [20, 24]. As the tumour cell
favors aerobic glycolysis (glycotic energy production over oxidative phosphorylation, even

64

in the presence of oxygen) [40], this leads to an accumulation of protons within the cell,
reducing pH. Na+/H+ antiport is the major mechanism used to reduce the concentration of
intracellular protons [19]. As protons are pumped out, sodium moves into the cell,
increasing its intracellular concentration. An acidic extracellular environment is also
favored by the cancer cells, as it aids in cell motility [41] and invasiveness [42].
In this study, we performed diffusion weighted imaging (DWI) in conjunction with
mpMRI and sodium-MRI. Our DWI data shows that ADC values were not strongly
correlated with Gleason score. Data from individual patient, patient cohort data, and cohort
average data showed little association between ADC measurements and Gleason score.
The ADC measurements recorded in this study agreed with values previously reported in
prostate cancer by Hambrock et al. [13]. Previous studies have shown that ADC can be
used as an imaging biomarker of cell density in glioma, ovarian and lung cancer; however,
only moderate correlations were seen in prostate cancer between ADC and cell density
[17]. Other research has demonstrated limitations in characterizing dispersed prostatic
lesions from normal tissue in the peripheral zone using T2-signal change [43]. This study
examined changes in T2-weighted contrast in relation to Gleason grade. Changes in T2weighted contrast in the prostate can be due to many factors. Kirkham et al. showed that
benign abnormalities like chronic prostatitis, hyperplasia, scars, atrophy and post-biopsy
hemorrhage all lead to hypo-intense signal in T2-weighted images. We observed a weak
and insignificant correlation coefficient between DT2 data and Gleason score; however, all
averaged DT2 data in lesions were negative, indicating that signal did decrease in lesions
compared to healthy tissue. This result has been reported in the literature [44]. The decrease
in T2-signal was not correlated with Gleason grade. Patient cohort data displayed a
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statistically significant correlation between ADC and DT2. Comparisons between ADC and
T2-contrast have been reported in the literature with similar results [44]. Additionally, we
showed that ADC and DT2 were both not significantly associated with TSC. The correlation
between ADC and DT2 is likely a correlation between cellular density measurements.
However, cell density information alone doesn’t necessarily provide reliable
characterization of a lesion [43]. The addition of DTSC to supplement mpMRI has the
potential for non-invasive lesion characterization. Further, DTSC has imminent
translational potential to help direct image guided biopsy. Sodium-MRI affords clinicians
accurate, non-invasive lesion classification; this may help with biopsy needle trajectory
planning, decreasing under sampling of clinically significant foci and repeated negative
biopsies.
In the current study, the spatial resolution of sodium-MRI was ~5 mm3 vs. ~0.5
mm3 for proton imaging. A broad-banded Fast Gradient-Recalled-Echo pulse sequence
with a Cartesian k-space trajectory was employed in this study. 3D-Spiral or radial pulse
sequences, which are optimized for fast T2 relaxation and efficient coverage of k-space for
sodium-MRI, have demonstrated the potential for improved SNR [45-47]. Further
development in this area could potentially increase spatial resolution and/or reduce
acquisition times for sodium-MRI in the prostate. An inherent limitation of a surface ER
coil is the receive profile, in which the signal requires sensitivity correction due to the
inhomogeneous receive profile. This is an issue for all prostate MRI (including 1H MR),
where high-resolution imaging often requires the use of an ER coil. Our DTSC data was
not affected by this problem as we corrected for the sensitivity profile of the rigid sodium
ER coil before analysis. The same correction was not performed on DT2 data, which was
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acquired with a separate inflatable (non-rigid) 1H ER coil. As a result, these data may be
subject to small errors. However, all identified regions analyzed in this study were situated
within the peripheral zone. The close-proximity of the peripheral zone to the ER coil
reduces the possible error in DT2 data without sensitivity correction. Future work can look
at previously acquired DCE imaging data, comparing metrics from the gadoliniumenhanced contrast to the accurately co-registered histological Gleason contours.
In conclusions, this research has demonstrated statistically significant increases in
in-vivo DTSC with increasing Gleason grade in individual patients. Accurate assessment
of lesions on an individual basis is important if sodium-MRI is to be used to characterize
tumour grade clinically. Further, a strong correlation was found between DTSC and
Gleason score in patient cohort data along with monotonic, statistically significant
increases in DTSC when cohort data were averaged together. The combination of sodiumMRI with mpMRI to form a non-invasive imaging assay promises improved detection,
characterization and surveillance of prostate lesions, which will ultimately increase the
confidence of men with early-stage disease to choose active surveillance instead of radical
treatment.
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2.7 Supplementary Figures

Figure 2-8. Supplementary figure 1. DTSC in relation to Gleason grade for all 10
individual patient data sets. Error bars represent standard error of the mean. No
significance is denoted by ns.
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Figure 2-9. Supplementary figure 2. ADC values in relation to Gleason grade for all
10 individual patient data sets. Error bars represent one standard deviation. No
significance is denoted by ns.
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Figure 2-10. Supplemental Figure 3. DT2 values in relation to Gleason grade for all 10
individual patient data sets. Error bars represent standard error of the mean. No
significance is denoted by ns.
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Chapter 3

3

Discussion, Future Work and Conclusions
Provided in this chapter will be an overall summary of this thesis work and some

limitations of this research. Additionally, some future directions for research in this area
will be explored, specifically: expanding the patient cohort, prostate cancer monitoring
using other imaging modalities, and the feasibility of using sodium-MRI to image other
disease models.

3.1 Discussion
3.1.1

Summary of Thesis Work
This thesis investigated the relationship between tissue sodium concentration

(TSC) and prostate cancer aggression. In this work, TSC was assessed using sodium
magnetic

resonance

imaging

(sodium-MRI)

and

Gleason-graded

whole-mount

histopathology was used as the ground truth for prostate cancer aggression. In this thesis
work, I began my contribution to the image analysis by registering all acquired imaging
data using a previously validated registration pipeline [1]. An in-depth explanation of the
step-by-step process used for this registration is provided in Appendix A-1. After
registration, Gleason contours are overlaid onto imaging data; allowing for accurate
comparison of cancer stage (Gleason grade) to all imaging data. This rigorous process
ensured that a specific voxel signal intensity from mpMRI or sodium-MRI data could be
correctly associated with a specific Gleason grade found on the histology sections. Figure
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3-1 provides a visual depiction of this process, where areas of a particular Gleason score
on a histopathology section are carefully identified (Gleason 4+3 is the Gleason score used
in the Figure 3-1 example) as masks of a specific Gleason score. Then, accurate registration
ensures that when this mask is overlaid onto the imaging data, we can extract regional
voxel signal intensity and compare that to the Gleason score of that area.

Figure 3-1. Procedure for building pathology masks. Gleason contours (panel a) are
used to build a pathology mask for one specific Gleason grade (panel b). In this
illustration Gleason 4+3 is used. The red arrows indicate how the masks are built in
the exact shape and size of the corresponding Gleason contour. These masks are then
overlaid onto imaging data (panel c). In this illustration, TSC values acquired with
sodium-MRI data is used. A Gleason grade legend and TSC signal intensity scale are
shown in the top right panel.
In this research, Gleason grade was compared to three sets of imaging data collected
prior to each patient’s prostatectomy surgery. These data were: apparent diffusion
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coefficients (ADC) assessed by diffusion-weighted imaging, T2-weighted images, and
tissue sodium concentration measurements assessed by sodium-MRI. This work was the
first-in-man study to compare and correlate the relationship between TSC and Gleason
score. The sodium ion has many important functions in the body; it has been previously
demonstrated to be a sensitive indicator of tumour cell motility and metabolism. Tumour
metabolism, specifically the influence of the Warburg effect in cancerous tissue, leads to
an increase in sodium ion concentration inside of the cell. Assuming a relatively constant
extracellular tissue sodium concentration due to tissue perfusion [2], increases in TSC from
normal tissue can then be hypothesized to be downstream effects of tumour cell
metabolism. All sodium signal detected in this imaging was from endogenous sodium ions.
In our study protocols, no sodium was administered to patients prior to imaging. However,
as alluded to, many normal metabolic processes influence tissue sodium concentration
levels in the body [3]. This highlights the potential for differences in baseline sodium levels
between patients. If sodium-MRI is to be translated to clinical use, methods to account for
the differences in sodium between patients must be considered. In this study, percent
changes of TSC were assessed, allowing for regional assessment of changes in TSC
associated with tumour grade in an individual patient. For this thesis, ∆TSC was used to
denote the percent changes in tissue sodium concentration. The same percentage change
method was used when analyzing T2-weighted images, denoted as ∆T2. These calculations
were done using Equation 2.1 (∆TSC) and Equation 2.2 (∆T2), described in Chapter 2,
subsection 2.3.7. Imaging data in this thesis were collected across the whole prostate,
sampling all zones of the gland. Data analysis was performed on the Gleason contours
which were localized to the peripheral zone as research suggest that up to 80% of prostatic
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cancers arise in this zone [4]. Additionally, proximity of the peripheral zone to the
endorectal receive coil provided the highest SNR and lowest measurement uncertainties
for the TSC analysis.
From our patient cohort of ten men, all with biopsy-proven prostate cancer, data
were analyzed on an individual patient basis and then averaged together. TSC increases
between Gleason grades in our data set were tested for statistical significance at the 0.05
level (p<0.05) using a one-way ANOVA and follow up Tukey test for all cases which had
more than two Gleason grades available for comparisons (n = 8). Cases which had only
two Gleason grades present on histology sections were tested for significance at the 0.05
level using an unpaired t-test (n = 1). Datasets where there were only one Gleason grade
present are not included in individual patient statistical analysis (n = 1). The strength of the
associations between whole patient cohort imaging data and Gleason grade were tested
using a Spearman’s non-parametric ranked correlation, producing the correlation
coefficient, rs. Sodium-MRI has shown promise as complementary imaging modality to
mpMRI, which together would provide patients with a non-invasive imaging biopsy, able
to localize in vivo cancer and then determine the cancer’s aggression. Therefore, the clinical
translatability of sodium-MRI as a useful assessment tool is grounded in its potential ability
to characterize lesions on an individual patient basis. The results of this thesis work show
that individual ∆TSC values displayed an increasing trend with Gleason grade for all
patients

where

more

than

one

Gleason-scored

lesion

type

was

present

(n = 9). Furthermore, feasible clinical translation requires the ability to differentiate
between low- and high-risk prostate cancer, where the former is monitored with active
surveillance and latter receives immediate intervention [5]. The widely accepted Gleason
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grade distinction between these treatment options is between Gleason scores 3+4 and 4+3
[6]. Of the ten men analyzed, six possessed clinically significant, high-grade lesions (≥
Gleason 4+3). Out of these six clinically significant cases, four displayed statistically
significant increases across the threshold described above. These data have been graphed
in Figure 2-8, within the Supplementary Figures section of Chapter 2. In total, six of the
nine cases used for data analysis displayed statistically significant increases in ∆TSC with
Gleason grade, this is in addition to the increasing trend, which was observed in all ∆TSC
data sets. When averaged together, the patient cohort ∆TSC data showed statistically
significant increases between all grades (p < 0.001) (Figure 2-4). Additionally, patient
cohort data possessed a significant correlation with Gleason grade (rs = 0.791, p < 0.01).
The relationship between apparent diffusion coefficient (ADC) and Gleason grade
has been previously examined and reported in the literature [7]. Reduced ADC values
within tissue has been related to increased cellularity and membrane integrity. However,
since ADC is not directly detecting metabolites which are inherently related to tumour
metabolism, it is harder to assert that ADC values are unequivocally related to tumour
aggression. This thesis work examined ADC values, measured by DWI, and compared
them to histological Gleason scores. The results suggest that the association between ADC
and tumour aggressiveness is not as robust as with TSC and lesion characterization using
ADC data alone is not reliable for an individual patient. In this limited study, examination
of ADC values from individual patients indicated a much weaker association with lesion
grade (Figure 2-9). Some individual patient datasets possessed an inverse relationship
between ADC values and increasing tumour grade (Patients 7, 8, 9, 10), a result seen in
previous literature [7]; however, the majority of the cases possessed no overall trend (n =
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5). Averaged patient cohort data (Figure 2-5) possessed similar results to the individual
patients, as statistically significant differences were recorded between all grades (p < 0.05);
however, this was not accompanied by any trend in the data, assessed by the Spearman’s
correlation (rs = -0.306, p = 0.079).
Previous research has also looked at how quantitative T2 contrast on T2-weighted
images, are related to prostate cancer. The results are mixed, with some research displaying
no difference in T2 values between cancerous and healthy tissue [8], while other studies
show that highly dense cancers have reduced T2 contrast in comparison to healthy tissue
[9]. For characterizing lesions this can be problematic, as low signal intensity on T2weighted prostate images can also be attributed to non-cancerous prostatic conditions [8].
The data presented in this research from individual patients show that changes in T2-signal
intensity from healthy tissue (∆T2) had very little correlation with Gleason score (Figure 210). Three of the nine cases possessed the expected inverse relationship of ∆T2 with
Gleason grade. Statistical significance was seen in seven of the none cases, but only two
were also accompanied by a decreasing trend. Averaged patient cohort data (Figure 2-6)
displayed similar results to the individual data, with some statistical significance recorded
(p < 0.05), but this was paired with an insignificant data trend (rs = -0.069, p = 0.699).
In this thesis, we have highlighted the strong relationship between tissue sodium
concentration measurements and histological Gleason grade. In this work, sodium-MRI
was acquired in conjunction with mpMRI on men with biopsy-proven prostate cancer.
These data were then accurately co-registered to Gleason-graded whole-mount
histopathology. This allowed for direct comparison of imaging data to Gleason score.
Imaging data included ADC values, T2-weighted images, and TSC data. The sodium ion
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has many important functions in tissue and has been previously demonstrated to be a
sensitive indicator of tumour cell motility and metabolism. The work of this thesis was the
first-in-man comparison and correlation of TSC values to Gleason grade. The results
reported in this thesis work suggest that TSC assessed by sodium-MRI was more capable
to distinguish between low- and high-grade prostate lesions than ADC measurements and
T2-weighted image contrast.

3.1.2

Limitations on Study Methodology
This research has several limitations. First, we assessed data from ten men, an n

value that is often considered to be small in a clinical setting. This was a difficult limitation
to avoid, as men needed to first fall within the studies inclusion criteria. After selecting
men who were candidates for the IGPC-2 study, they also needed to consent for sodiumMRI in addition to the standard protocols of the study. A total of seventeen men consented
for sodium-MRI in addition to standard MRI. Of these seventeen men, four patients did
not have high enough SNR to allow for accurate analysis, one withdrew due to a screen
failure, one man did not return for prostatectomy surgery after imaging, and one patient
showed no cancer in his prostate when the tissue went for Gleason grading. This left ten
men who had successful imaging, prostatectomy surgery and subsequently tissue Gleason
grading. Further, one of the ten datasets possessed only one Gleason grade (Gleason 3) on
histology sections Therefore, analysis of imaging data changes between Gleason grades
not possible. However, these data were included in patient cohort data analysis. An
expanded cohort is planned after securing further funding to address this limitation (see
section 3.2.1).
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3.2 Future Work
3.2.1

Patient Cohort Expansion
This thesis work has presented the research from a pilot study, demonstrating that

sodium-MRI has utility to be used in the clinic as complementary imaging data to multiparametric-MRI. Together these techniques may be used as a non-invasive imaging biopsy,
with high specificity to characterize in vivo prostate cancer grade. This information would
be invaluable to clinicians and men with prostate cancer, as it has the potential to increase
confidence in risk stratification decisions and to improve surveillance of low-risk disease.
To facilitate this, these preliminary results need to be verified in a larger patient cohort
with higher throughput. Future studies are planned, which will incorporate a dual-tuned
ER receive coil, facilitating inherent registration of mpMRI and sodium-MRI data. This
will eliminate a time-consuming co-registration step involving these data, as they will be
obtained serially without changing RF coils (see Appendices A-1).

3.2.2

Additional Imaging Modalities for Prostate Cancer Detection
Sodium-MRI has been shown to be a sensitive indicator of prostate cancer grade,

but additional imaging modalities can be useful to detect this disease, providing insight
about the tumour tissue that is not evident through sodium-MRI. Dynamic-contrast
enhanced MRI data can be collected in conjunction with other mpMRI contrasts. These
data can be registered to Gleason graded histology using the same registration pipeline
used in this thesis’s research. Therefore, DCE-MRI wash-in, wash-out rates may be
compared to Gleason score as further information for localization and characterization of
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prostate cancer. Prostate-specific membrane antigen (PSMA) is a cellular surface protein
whose expression increases 100-1000-fold in prostate cancer. This has made PSMAligands, which are radio-labeled to allow for detection using positron emission tomography
(PET), a new sensitive tool for localizing prostate cancer. Additionally, labeled PSMAPET ligands have been previously shown to have high sensitivity for prostate cancer cell
metastases, an area of obvious clinical significance [10]. The superior anatomical
delineable of multi-parametric-MRI has shown utility for locating suspicious regions in the
human prostate [11]. Therefore, potential clinical workflow could involve mpMRI to locate
potential lesions and sodium-MRI to characterize the lesion grade.

3.2.3

Using Sodium-MRI in Other Disease Models
Chapter 1-Section 1.3.2, described altered cellular metabolism within tumour cells

involving upregulation of glycolysis (known as the Warburg Effect). This is not limited to
prostate cancer and, as one might expect, increased TSC has also been observed in other
cancers, including brain and breast cancer [12, 13]. Previous research has identified that
the sodium-hydrogen antiporter (NHE1), one of the players responsible for increased
sodium influx in tumour tissue, is ubiquitously expressed across cellular membranes of
different tissue, including those within the breast and brain cells. In 2007, research by
Ouwerkerk et al. showed that breast lesions significantly increased in tissue sodium
concentration compared to unaffected tissue [13]. Additionally, research has suggested that
the activity of NHE1 plays a role in the metastasis potential of breast cancer [14]. Brain
cancer is a devastating diagnosis to patient, and approximately 1 in 123 Canadians will
develop some form of brain cancer during their lifetime [15]. Glioma is the most common
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form of primary brain cancer, accounting for roughly 80% of malignant brain tumours [16].
Previous studies have used sodium-MRI to quantify TSC in malignant brain tumours [12].
These results showed that sodium concentration in brain tumours were elevated compared
to healthy brain tissue. Therefore, this highlights potential utility of using sodium-MRI
assessed TSC to monitor tissue changes other tumour types such as breast and brain cancer.
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3.3 Conclusions
Men diagnosed with prostate cancer are often faced with the stressful and uncertain
decision about whether the best treatment of their cancer is active surveillance or radical
treatment. Under diagnosis of prostate cancer is a concern due to the limited sample
volumes obtained from prostate biopsy. This places a psychological burden on patients
who have been diagnosed through biopsy with potentially less aggressive cancer because
the widely-held belief is that cancer should be met head-on with curative treatment. Due to
this, patients look to reject active surveillance protocols even if they are diagnosed with
low-risk prostate cancer. These men instead opt for radical treatment, even if it may not be
necessary for them. Accurate whole-gland lesion characterization tools can improve this
situation. This research was undertaken to assess the relationship between data from
magnetic resonance imaging contrasts and prostate cancer aggression. Imaging techniques
are attractive solutions as they allow for whole-gland lesion assessment, creating a potential
niche for non-invasive imaging assays. For this study, the “ground truth” for prostate
cancer aggression was Gleason-graded whole-mount histopathology which was coregistered to imaging data. Imaging data collected included T2-weighted imaging,
diffusion-weighting imaging, and sodium-MRI. The results of this research show that
endogenous tissue sodium concentration, assessed by sodium-MRI, was better than the
mpMRI contrasts at unequivocally identifying the aggressiveness of prostate lesions.
Furthermore, the combination of sodium-MRI with mpMRI could provide the basis for an
imaging biopsy, providing accurate complementary information to patients related to their
prostate cancer aggressiveness. This may be another small step along the path toward
precision medicine.
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Appendices A-1: In-Depth Description of the Image CoRegistration Pipeline
An important aspect to success of the research presented in this thesis was the
accurate co-registration of all imaging data to the whole-mount histopathology slices which
were Gleason graded by a pathologist assistant and subsequently confirmed by an expert
genitourinary pathologist. For this study and in the clinic, Gleason grading of tissue
samples is the gold standard for assessment of prostate cancer aggression. Therefore,
accurate registration is very important to ensure that the extracted imaging voxel signal
intensity is correctly compared to that voxels pathological Gleason score. In this
description, we will be referring to the imaging data shown in Figure 0-1, which has been
adapted from a previously shown figure in Chapter 2 (Figure 2-1). These data include: in
vivo high-resolution T2-weighted images, in vivo low-resolution T2-weighted images, ex
vivo T1 and T2-weighted image sets, whole-mount digitized histopathology, in vivo sodiumMRI images.
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Figure 0-1. The imaging volumes used in this study and their position along the
registration pipeline. Step 1 (not shown) is preparation of the prostate specimens for
high-resolution bright-field scanning and subsequent Gleason grading. Digitized
whole-mount histopathology with Gleason graded lesions (panel a) are registered to
the ex vivo T2-weighted image (panel b) through the process described in Step 2. In
vivo sodium-MRI data (panel c) are registered to the lower-resolution In vivo T2weighted volume (panel d) through the process described in Step 3a. The lowresolution In vivo T2-weighted image set is registered to the high-resolution In vivo T2weighted image set (panel e) through the Step 3b’s procedure. Finally, ex vivo T2weighted images are registered to high-resolution In vivo T2-weighted images through
the Step 4 procedure.

Step 1: Prostate Specimen Preparation
The image registration pipeline begins after radical prostatectomy, where excised
prostates are fixed in formalin and laced with MRI-visible fiducial markers (3 internal and
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7 external). These fiducial markers are designed to be soft to avoid tissue disruption [1].
This is because a pathologist’s evaluation of the excised prostate tissue affects a patient’s
clinical outcomes, so these fiducials should not influence that. These prostate sections are
then MR imaged ex vivo. After imaging, the prostate specimens are sliced into sections 4.4
mm apart [1]. This slicing is important to ensure that each cut is along the plane acquired
during imaging or at least as nearly parallel as possible. This step was performed by
collaborator Cathie Crukley.

Step 2: Registration of Ex Vivo MR Images to Histology
After slicing, these histology sections are registered to the previously acquired T1and T2-weighted ex vivo image set. Image registration was done on the T1-weighted image,
but the T2-weighted images are acquired serially and are therefore registered inherently
using the exact same fiducials. This step was performed by Dr. Aaron Ward’s group,
specifically Chapter 2 co-author Peter Martin.

Step 3: Registration of In Vivo MR Image Sets
Step 3a) The registration between the low-resolution T2-weighted image set and the
sodium-MRI image sets was a rigid automatic registration. Both images were taken using
the same endorectal (ER) receive radiofrequency (RF) coil in the same MR exam which
facilitated this registration using fixed fiducial points which were enclosed in the reference
vials used for calculation of absolute TSC values. The reference vials were situated within
the ER probe itself, so applicator of a simple rotation allowed for registration of these image
sets.
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Step 3b) The deformable co-registration of the low-resolution T2-weighted image set
acquired with the rigid 23Na ER probe to the high-resolution T2-weighted image set taken
with an inflatable 1H ER probe. To perform this registration, approximately 10-15
preliminary fiducial points are placed on physiologically relevant regions of interest (ROI)
that are identifiable on both imaging volumes. These ROI’s include areas of hypo-intense
signal such as benign prostatic hyperplasia and hyper-intense cystic spaces [1]. It is
important these some of the preliminary fiducials are placed around the perimeter of the
prostate, to allow for accurate overlay. Once the 10-15 homologous preliminary fiducial
points are specified, the user selects both an input volume and a reference volume. The
input volume will be deformed to the reference volume during registration. After this
selection, the two image sets and associated fiducial points are plugged into a non-rigid,
interactive thin-plate spline (TPS) extension [2] within the 3D Slicer software (Surgical
Planning Laboratory, Harvard Medical School, Boston, MA, USA, Version 4.3.1). The
TPS module deforms the input volumes to fit the reference volume based upon the
specified fiducial points. After the rough registration of the two volumes using the 10-15
points, 35-40 more fiducial points are chosen on the images. As each new fiducial point is
chosen, a real-time deformation of the input volume to the reference volume is performed.
The registering scientist can delete old fiducial points that they decide are not necessary or
are not as accurate as originally thought. On average, a full registration will have 50 fiducial
points.
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Step 4: Registration of Ex Vivo and In Vivo MR Image Sets
The last step in this study’s registration pipeline, is the co-registration of both the
ex vivo imaging volumes (T1- and T2-weighted) with the high-resolution T2-weighted image
set. The T1- and T2-weighted image sets are automatically registered to each other, so we
only needed to register the T2-weighted image sets for full image registration. We use the
T2-weighted ex vivo images because registration requires comparison of ROI’s which have
homologous contrast enhancement with respect to surrounding tissue. The procedure for
this non-rigid, deformable registration is the same as explained in Step 3. When the pipeline
has been successfully completed, we expect an in vivo MRI to histopathology coregistration error of ~ 1.5 mm [1].
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